Skip Navigation
Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​
NIH HHS News Release Logo

National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Thursday, June 4, 1998

Media Contact:
June Wyman
(301) 402-1663

niaidnews@niaid.nih.gov

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Scientists Identify Molecular Target for Tuberculosis Drug Treatment

In a study with major implications for improving tuberculosis (TB) treatment, researchers have identified the exact part of the disease-causing microbe that is targeted by isoniazid, the most widely used TB medication.

Tuberculosis now infects some 1.9 billion people worldwide, one-third of the world’s population. The World Health Organization projects that in the next decade, 300 million more people will become infected, 90 million will develop tuberculosis and 30 million will die from it. As the number of new cases increases, multi-drug-resistant strains of Mycobacterium tuberculosis have made treatment more and more difficult.

"Tuberculosis cannot be fully controlled with existing medications," says NIAID Director Anthony S. Fauci, M.D. "We desperately need new drugs to combat this worldwide public health problem."

The new findings will allow scientists to understand and predict how certain strains of M. tuberculosis become drug-resistant. The research also has generated a way to screen potential anti-TB drugs very fast, accelerating the pace of drug development.

"With tests based on these findings, we’ll be able to screen thousands of anti-TB compounds in an assay that takes only a few minutes, instead of the three weeks required for normal tests," says Clifton E. Barry III, Ph.D., of the National Institute of Allergy and Infectious Diseases (NIAID). "I think we have the perfect new tool for developing new drugs against TB."

The research was a collaborative project of Dr. Barry’s team and NIAID grantee James M. Musser, M.D., Ph.D., and colleagues at the Baylor College of Medicine in Houston, Texas. Their report appears in the June 5, 1998, issue of Science.

Although isoniazid has been widely used to treat people with tuberculosis, until now no one knew exactly how it worked, and why it no longer works on certain TB strains. Dr. Barry and his colleagues discovered that the drug attacks a protein, called KasA, that the bacterium needs to build its cell wall, thus preventing the growth of M. tuberculosis cells. They also found that mutations in the gene that codes for this protein render TB cells invulnerable to the drug, resulting in antibiotic-resistant TB strains.

With the knowledge that KasA is critical to bacterial growth, scientists can work on designing drugs that specifically attack this molecule. They also can devise tests, or assays, to screen new anti-TB drugs for their power to target the KasA protein.

Such tests are already in the works. Through a CRADA (Cooperative Research and Development Agreement), NIAID scientists and researchers at Pharmacopeia in Princeton, N.J., have devised a fast, high-volume method for screening potential anti-TB compounds. Together they plan to test more than 2 million compounds for anti-TB action.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​​​

Last Updated June 04, 1998